Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Papillary Cell Renal Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01130519
What this trial is testing

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Who this might be right for
HLRCCSporadic Papillary Renal Cell Cancer
National Cancer Institute (NCI) 83
Early research (Phase 1)Study completedNCT00005842
What this trial is testing

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Cancer
National Cancer Institute (NCI) 24
Not applicableNot Yet RecruitingNCT07243067
What this trial is testing

Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer

Who this might be right for
Renal Cell CarcinomaClear-cell Renal Cell CarcinomaPapillary Renal Cell Carcinoma+2 more
Mayo Clinic 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT04413123
What this trial is testing

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Who this might be right for
Papillary Renal Cell CarcinomaUnclassified Renal Cell CarcinomaTranslocation Renal Cell Carcinoma+5 more
Bradley A. McGregor, MD 60
Large-scale testing (Phase 3)Study completedNCT00492258
What this trial is testing

Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer

Who this might be right for
Kidney Cancer
Medical Research Council 1,656
Testing effectiveness (Phase 2)Study completedNCT00688753
What this trial is testing

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe

Who this might be right for
CarcinomaRenal CellNon Clear Cell Renal Carcinoma+2 more
Novartis Pharmaceuticals 92
Testing effectiveness (Phase 2)Study completedNCT02019693
What this trial is testing

The MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Who this might be right for
Kidney Cancer
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Study completedNCT01727089
What this trial is testing

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Who this might be right for
Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CarcinomaStage IV Renal Cell Cancer+2 more
National Cancer Institute (NCI) 59
Early research (Phase 1)Study completedNCT00098943
What this trial is testing

NGR-TNF in Treating Patients With Advanced Solid Tumors

Who this might be right for
Colorectal CancerHead and Neck CancerKidney Cancer+1 more
European Organisation for Research and Treatment of Cancer - EORTC 70
Testing effectiveness (Phase 2)Study completedNCT01164228
What this trial is testing

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

Who this might be right for
Kidney Cancer
ECOG-ACRIN Cancer Research Group 87
Testing effectiveness (Phase 2)Study completedNCT00126503
What this trial is testing

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Who this might be right for
Chromophobe Renal Cell CarcinomaClear Cell Renal Cell CarcinomaPapillary Renal Cell Carcinoma+3 more
National Cancer Institute (NCI) 73
Testing effectiveness (Phase 2)Ended earlyNCT00323791
What this trial is testing

Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Who this might be right for
Kidney Cancer
University of Medicine and Dentistry of New Jersey 100
Testing effectiveness (Phase 2)Ended earlyNCT02495103
What this trial is testing

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaHereditary LeiomyomatosisRenal Cell Cancer
National Cancer Institute (NCI) 7
Early research (Phase 1)Study completedNCT01198184
What this trial is testing

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Who this might be right for
Endometrial Papillary Serous CarcinomaRecurrent Endometrial CarcinomaRecurrent Renal Cell Cancer+5 more
National Cancer Institute (NCI) 18
Not applicableStudy completedNCT06339138
What this trial is testing

Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

Who this might be right for
Chromophobe Renal Cell CarcinomaClear Cell Papillary Renal TumorClear Cell Renal Cell Carcinoma+3 more
Mayo Clinic 589
Early research (Phase 1)Study completedNCT01100619
What this trial is testing

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Who this might be right for
Papillary Thyroid CancerFollicular Thyroid CancerHuerthle Cell Thyroid Cancer+1 more
Exelixis 40
Testing effectiveness (Phase 2)WithdrawnNCT04603365
What this trial is testing

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Who this might be right for
Clear Cell Papillary Renal NeoplasmCollecting Duct CarcinomaHereditary Leiomyomatosis and Renal Cell Carcinoma+8 more
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00459875
What this trial is testing

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Who this might be right for
Kidney Cancer
Memorial Sloan Kettering Cancer Center 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT04071223
What this trial is testing

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Who this might be right for
Advanced Renal Cell CarcinomaChromophobe Renal Cell CarcinomaClear Cell Renal Cell Carcinoma+6 more
National Cancer Institute (NCI) 134
Testing effectiveness (Phase 2)Study completedNCT00465179
What this trial is testing

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

Who this might be right for
Renal Cell CancerKidney Cancer
M.D. Anderson Cancer Center 61
Next Page